Breast Neoplasm

UMLS: C1458155
Basic Information
Severity Level:
Moderate
Definition:
Tumors or cancer of the human BREAST.
UMLS ID:
C1458155
MeSH ID:
D001943
Synonyms:
Breast Neoplasm
Breast Neoplasm
Breast Neoplasms
Breast Tumor
Breast Neoplasm
Breast Tumor
Breast Tumour
Breast--Tumors
Neoplasm Of Breast
Neoplasm Of Breast
Neoplasm Of The Breast
Neoplasm Of The Breast
Neoplasm, Breast
Tumor Of Breast
Tumor Of Breast
Tumor Of The Breast
Tumour Of Breast
Tumours Of The Breast
Classification Hierarchy
MeSH Tree Number breakdown for C1458155
C04
Neoplasms
Category: Neoplasms Parent: C (Diseases) Level: 0
C04.588
Neoplasms by Site
Category: Neoplasms Parent: C04 Level: 1
C04.588.180
Breast Neoplasms
Category: Neoplasms Parent: C04.588 Level: 2 Tree Number: C04.588.180
C17
Skin and Connective Tissue Diseases
Category: Skin and Connective Tissue Diseases Parent: C (Diseases) Level: 0
C17.800
Skin Diseases
Category: Skin and Connective Tissue Diseases Parent: C17 Level: 1
C17.800.090
Breast Diseases
Category: Skin and Connective Tissue Diseases Parent: C17.800 Level: 2
C17.800.090.500
Breast Neoplasms
Category: Skin and Connective Tissue Diseases Parent: C17.800.090 Level: 3 Tree Number: C17.800.090.500
Similar ADEs in This Classification
Ca - Skin Cancer
UMLS: C0007114
37%
Cutaneous Neoplasm
UMLS: C0037286
37%
Bloodgood Disease
UMLS: C0016034
32%
Enlarged Male Breast
UMLS: C0018418
32%
Breast Cyst
UMLS: C0006144
31%
Neoplasm Of Sebaceous Gland
UMLS: C0036503
28%
Abdomen Tumor
UMLS: C0000735
28%
Head And Neck Neoplasm
UMLS: C0018671
28%
Neoplasm Of Pelvis
UMLS: C0030793
28%
Neoplasm Of Soft Tissue
UMLS: C0037579
28%
Neoplasm Of Thorax
UMLS: C0039981
28%
Cancer Of Head And Neck
UMLS: C0278996
28%
ADE Molecular Mechanism Mapping

Drug-ADE-Human Protein Triplets

Molecular mechanism triplets showing drug-adverse event-protein relationships

6881 Total Triplets
443 High Confidence
Loading Drug-ADE-Protein triplets...
Personalized Drug-Protein-ADE Network

Comprehensive Information for Personalized ADE

Comprehensive Information and Reliability for Drug-ADE Association

Drug Confidence Filter
DTA Confidence Level
Layout Style
Show Labels
Total Drugs
538
2 High | 25 Medium | 511 Low Confidence
Total Proteins
466
Target proteins associated with this ADE
Drug-Protein-ADE association
27097
14 Known | 429 High | 6438 Middle | 20216 Low Confidence
Confidence Profile
25%
Known/High/Middle-confidence interactions

This interactive network visualization shows the relationships between the top 50 drugs (ranked by case number) out of 538 total drugs associated with this adverse event, their known and potential off-target proteins, and the associated adverse effect. The connections indicate binding interactions and mechanistic pathways.

Adverse Drug Event (ADE)
Drug
Protein
Drug-Center
Human Protein-Center
confidence level

Drug Confidence Level Distribution

Drug Type Distribution

Loading ADE information...

Pharmacological Target Class Distribution

Top 8 Function Target Sub Classes

Loading target information...
The Introduction of Drug-AE Confidence Score Grade
Priority Level Score Range Description Evidence Characteristics
High Score ≥ 6.67
High-priority associations requiring immediate attention. 		Strong evidence across multiple dimensions with high statistical significance, robust association measures, and substantial case numbers. Warrant priority pharmacovigilance action. High P-value scores (significant Adjust-P), Strong ROR/PRR values, Substantial case numbers, Complete dimensional coverage, Minimal data filtering needed.
Medium 3.33 ≤ Score < 6.67
Medium-priority associations requiring careful evaluation.		 Moderate evidence quality with acceptable statistical significance and association strength. May need additional validation or monitoring before definitive action. Moderate P-value significance, Reasonable ROR/PRR measures, Adequate case numbers, Partial dimensional coverage, Some data quality considerations.
Low Score < 3.33
Low-priority associations with limited evidence strength. 		May represent weak signals, insufficient data, or associations requiring extensive additional investigation before any regulatory or clinical consideration. Weak P-value significance, Low association measures, Limited case numbers, Incomplete dimensional data, Significant data filtering applied.
PersDTA overview
The Introduction of Drug-AE Severity Score Grade
Severity Level Score Range Description Typical outcomes
Minimal 0 ≤ Score ≤ 0.387
Low severity ADRs requiring minimal intervention.		 Events that need medical attention to prevent permanent damage but without hospitalization or life-threatening consequences. Primarily RI (Required Intervention) outcomes, Outpatient management, Preventive measures, Early intervention prevents escalation.
Mild 0.387 < Score ≤ 0.861
Mild severity events requiring hospitalization.		 Mix of intervention-required and hospitalization cases with manageable clinical outcomes and good recovery potential. Mix of RI and HO outcomes, Initial or prolonged hospitalization, Active medical management, Generally favorable prognosis.
Moderate 0.861 < Score ≤ 1.500
Moderate ADRs resulting in permanent disability.		 Higher proportion of hospitalization and disability cases requiring intensive medical management and long-term care planning. Increased HO and DS outcomes, Permanent disability, Extended hospitalization, Rehabilitation required, Long-term functional impairment.
Severe 1.500 < Score ≤ 2.52
High severity life-threatening events with significant morbidity.		 Notable presence of disability and life-threatening outcomes requiring emergency intervention and intensive care management. Prominent DS and LT outcomes, Life-threatening events, Emergency intervention required, ICU admission, High risk of permanent consequences.
Critical 2.524 < Score ≤ 5.000
Critical life-threatening or fatal ADRs with maximum clinical impact.		 High proportion of life-threatening events and deaths with very strong drug-event associations requiring immediate regulatory action. Significant LT and DE outcomes, Fatal events, Emergency life-support measures, Immediate drug discontinuation, Regulatory safety alerts.
The Introduction of Drug-AE-Protein Confidence Score Grade
Confidence Level Relationships Description Evidence Types
Known/Valid Direct DTA relationships The drug-ADE, drug-target, and target-ADE associations are all derived from the same literature source. Experimental validation, Clinical evidence
High DT + TA + DA Two of the three associations (drug-ADE, drug-target, and target-ADE) are derived from the same literature source, while the third is validated by other literature. Multiple corroborating sources
Medium DT + TA + DA Two of the three associations (drug-ADE, drug-target, and target-ADE) are validated by separate literature sources. Partial evidence chain
Low TA + DT Only target-ADE and drug-target associations are validated by literature sources. Associative evidence only
Personalized ADE

Route and Formulation-specified Associations

Pharmaceutic Granularity for Route and Formulation specification

Administration Routes (Total: 439 cases across 11 routes)

Dosage Forms (Total: 202 cases across 12 forms)

Drug Route Analysis
Drug Form Analysis

Drug Route Analysis

Route Drug Name Case Number Confidence Score Confidence Level Severity Score Severity Level Details
Loading data...

Drug Form Analysis

Form Drug Name Case Number Confidence Score Confidence Level Severity Score Severity Level Details
Loading data...

Disease-stratified Associations

Personalized Granularity for Disease and Indication Stratification

Indication Name
Drug Name
Case Number
Confidence Score
Confidence Level
Severity Score
Severity Level
Details